Materials and methods for diagnosis of bladder cancer and monitoring recurrence thereof

A method of monitoring recurrence of bladder cancer in a patient, which method comprises contacting a sample of urothelial cells obtained from the patient with a set of detectably labeled probes comprising a locus-specific probe for c-myc, a locus-specific probe for AURKA, a centromeric probe for chromosome 7, and a centromeric probe for chromosome 17 under hybridization conditions, and determining the presence of chromosomal abnormalities, wherein the presence of chromosomal abnormalities involving at least two of the detectably labeled probes indicates that bladder cancer has recurred in the patient, whereupon recurrence of bladder cancer in the patient is monitored.

A set of probes comprising a locus-specific probe for c-myc, a locus-specific probe for AURKA, a centromeric probe for chromosome 7, and a centromeric probe for chromosome 17.

A kit comprising (a) a set of probes that enables diagnosis of bladder cancer, or monitoring the recurrence thereof, in a patient, wherein the set of probes comprises a locus-specific probe for c-myc, a locus-specific probe for AURKA, a centromeric probe for chromosome 7, and a centromeric probe for chromosome 17 and (b) instructions for diagnosing bladder cancer, or monitoring recurrence thereof, in a patient, wherein the instructions comprise determining in a sample of urothelial cells obtained from the patient the presence of chromosomal abnormalities, wherein the presence of chromosomal abnormalities involving at least two of the probes indicates that the patient has bladder cancer.